Characteristics | All RA patients | Longitudinal etanercept study |
---|---|---|
 | (N= 75) | (N= 16) |
Median age, years (range) | 57.0 (23 to 83) | 56.0 (41 to 66) |
Female/male (n) | 55/20 | 10/6 |
Median disease duration, years (range) | 7.0 (1 to 57) | 2 (1 to 13) |
RF-positive (%) | 77.0 | 68.8 |
Anti-CCP-positive (%) | 75.8 | 93.8 |
Median CRP, mg/dl (range) | 3.53 (0 to 113) | 4.40 (0.5 to 21.1) |
DMARDs (n) | Â | Â |
  Methotrexate | 42 | 13 |
  Azathioprine | 1 | 0 |
  Leflunomide | 4 | 1 |
  Anti-TNF | 7 | 0 |
  Anti-TNF + MTX | 2 | 0 |
  Abatacept | 1 | 0 |
  Hydroxychloroquine + MTX | 1 | 1 |
  Cyclosporin A | 1 | 0 |
  Cyclosporin A + MTX | 1 | 0 |
  Tocilizumab | 1 | 0 |
  Rituximab | 1 | 0 |
  Without | 13 | 1 |